×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Krystal Biotech touts topical gene therapy uptake, plots overseas launches
Fierce Pharma
After a 2023 approval from the FDA, Krystal Biotech has collected more than $95 million from its launch of Vyjuvek, the first treatment for...
1 week ago
Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB (NASDAQ:KRYS)
Seeking Alpha
Krystal Biotech is a promising biotech stock with strong revenue growth after the approval of its flagship product, VYJUVEK.
1 day ago
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
Simply Wall Street
Solid profit numbers didn't seem to be enough to please Krystal Biotech, Inc.'s ( NASDAQ:KRYS ) shareholders. Our...
3 days ago
Science
Krystal Biotech, Inc
Krystal Biotech has developed a differentiated vector platform focused on a number of indication areas including dermatology, respiratory, oncology,...
4 months ago
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call Transcript
Yahoo Finance
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call Transcript May 6, 2024 Krystal Biotech, Inc. misses on earnings expectations.
1 week ago
Krystal Biotech doses first subject in lung cancer drug trial
Clinical Trials Arena
Krystal Biotech has dosed the first subject in the Phase I KYANITE-1 clinical trial for its inhaled oncology candidate, KB707.
3 weeks ago
Krystal Biotech Shares Drop After 1Q Earnings Miss
MarketWatch
By Dean Seal Shares of Krystal Biotech slid after the company's first-quarter results came in below analyst expectations.
1 week ago
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
WICZ
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company,...
1 day ago
Krystal Biotech moves to next step in clinical trial
The Business Journals
Krystal Biotech has announced the first patient has joined a trial for its inhaled treatment for a solid lung cancer tumor.
3 weeks ago
Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research
Krystal Biotech (KRYS) delivered earnings and revenue surprises of -85% and 0.57%, respectively, for the quarter ended March 2024.
1 week ago